Psoriatic Arthritis - Seven-Market Drug Forecast and Market Analysis

Description

List of Tables

This new set to update and replace the previous psoriatic arthritis market analysis publication, Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028 (January 2020, GDHC186PIDR), which covered the forecast period 2018-28. This new publication covers the psoriatic arthritis market over the forecast period of 2023-33.

GlobalData estimated the total psoriatic arthritis market to be valued at $5.1 billion across the 8MM, with the US accounting for 80.4% of the market. The five major GlobalData estimated the value of the global PsA market to be $9.5 billion across the 7MM in 2023. By 2033, PsA sales across the markets are expected to grow to $13.5 billion, representing a compound annual growth rate (CAGR) of 3.6% over the 10-year forecast period.

Major drivers of growth in the PsA market over the forecast period include -

Launches of six new pipeline agents in PsA: Sotyktu (approved to treat plaque psoriasis [PsO]), icotrokinra, sonelokimab, Ilumya (approved to treat PsO), JNJ-4804, and zasokitinib.
Rise of small molecule therapies, both marketed and in development to treat PsA

The major barriers of growth in the PsO market during the forecast period include -

Loss of patent protection in the US for biologics, such as Janssen's Stelara (ustekinumab) in 2024 and Cosentyx (secukinumab) in 2029, and the subsequent launches of their corresponding biosimilars
Launch of apremilast generics in 2028 in the US
Passage of legislature in the US, both on the federal and state level, aimed to reduce drug prices

Key Highlights

In 2023, GlobalData estimates that sales of drugs in the PsA market was approximately $9.5 billion in 2023 in the 7MM. The global PsA market is expected to grow to $13.5 billion in 2033, at a Compound Annual Growth Rate (CAGR) of 3.6%.
Major drivers of the severe market growth over the forecast period are the -
Launches of six new pipeline agents in PsA: Sotyktu (approved to treat plaque psoriasis [PsO]), icotrokinra, sonelokimab, Ilumya (approved to treat PsO), JNJ-4804, and zasokitinib.
Rise of small molecule therapies, both marketed and in development to treat PsA

Scope

Overview of Psoriatic Arthritis, including epidemiology, symptoms, diagnosis, and disease management.
Annualized psoriatic arthritis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the psoriatic arthritis therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for psoriatic arthritis treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global psoriatic arthritis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global PsA therapeutics market from 2023-2033.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC307PIDR-7M

1 Psoriatic Arthritis: Executive Summary

1.1 Sunsetting older therapies, biosimilars, and generics dampen PsA market growth
1.2 Strategic positioning established by the PsO market
1.3 Lack of innovation provides market opportunity
1.4 Johnson & Johnson leads PsA pipeline assets with icotrokinra
1.5 What do physicians think?

2 Introduction

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology
3.2 Etiology
3.3 Genetic factors
3.4 Environmental and lifestyle factors
3.5 Pathophysiology

4 Epidemiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Diagnosed incident cases of PsA
- 4.4.4 Diagnosed prevalent cases of PsA
- 4.4.5 Diagnosed prevalent cases of PsA by type
- 4.4.6 Diagnosed prevalent cases of PsA by severity
- 4.4.7 Diagnosed prevalent cases of PsA with comorbidity
- 4.4.8 Diagnosed prevalent cases of PsA with psoriasis
4.5 Epidemiological forecast for PsA (2023-33)
- 4.5.1 Diagnosed incident cases of PsA
- 4.5.2 Sex-specific diagnosed incident cases of PsA
- 4.5.3 Age-specific diagnosed incident cases of PsA
- 4.5.4 Diagnosed prevalent cases of PsA
- 4.5.5 Sex-specific diagnosed prevalent cases of PsA
- 4.5.6 Age-specific diagnosed prevalent cases of PsA
- 4.5.7 Diagnosed prevalent cases by type
- 4.5.8 Diagnosed prevalent cases by severity
- 4.5.9 Diagnosed prevalent cases by comorbidity
- 4.5.10 Diagnosed prevalent cases of PsA with psoriasis
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview
5.2 Key opinion leader insights on disease management

6 Current Treatment Options

6.1 Overview
- 6.1.1 Tumor necrosis factor inhibitors
- 6.1.2 IL-17 Inhibitors
- 6.1.3 IL-23 Inhibitors
- 6.1.4 Janus kinase inhibitors
- 6.1.5 Other targeted synthetic disease modifying anti-rheumatic drugs

7 Unmet Needs and Opportunity Assessment

7.1 Overview
7.2 Highly efficacious therapies
7.3 Biomarkers
7.4 Treating PsA and its comorbidities
7.5 Identifying the subclinical state of PsA

8 R&D Strategies

8.1 Overview
- 8.1.1 Market significant shift towards small molecules
- 8.1.2 Development with an eye on market positioning
8.2 Clinical trials design
- 8.2.1 Active comparator trials

9 Pipeline Assessment

9.1 Overview
9.2 Promising drugs in clinical development
- 9.2.1 JNJ-4804
- 9.2.2 Ilumya
- 9.2.3 Icotrokinra
- 9.2.4 Sonelokimab
- 9.2.5 Zasocitinib
- 9.2.6 Sotyktu

10 Pipeline Valuation Analysis

10.1 Overview
10.2 Competitive assessment
- 10.2.1 Biologic therapies
- 10.2.2 Small molecule therapies

11 Current and Future Players

11.1 Overview
11.2 Deal-making trends

12 Market Outlook

12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
- 13.4.1 Key opinion leaders
- 13.4.2 Payers
13.5 Primary research - prescriber survey
13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologist
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence
13.7 Contact Us

Product Code: GDHC307PIDR-7M

List of Table

List of Tables

Table 1: PsA: key metrics in the 7MM
Table 2: Risk factors and comorbidities for PsA
Table 3: 7MM, diagnosed prevalent cases by severity (N), men and women, ages >=18 years, 2023
Table 4: Treatment Guidelines for PsA
Table 5: Top completed deals in PsA market by value, 2018-23
Table 6: Disease PsA market - global drivers and barriers, 2023-33
Table 7: Key events impacting sales for PsA in the US, 2023-33
Table 8: Disease PsA market - drivers and barriers in the US, 2023-2033
Table 9: Key events impacting sales for PsA in the 5EU, 2023-33
Table 10: PsA market - drivers and barriers in the 5EU, 2023-33
Table 11: Key events impacting sales for PsA in Japan, 2023-33
Table 12: PsA market - drivers and barriers in Japan, 2023-33
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for PsA in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in PsA during the forecast period
Figure 3: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara
Figure 4: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq
Figure 5: 7MM, diagnosed incidence of PsA (cases per 100,000 population), men and women, ages >=18 years, 2023
Figure 6: 7MM, diagnosed prevalence of PsA (%), men and women, ages >=18 years, 2023
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PsA
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PsA
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PsA by type
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PsA with comorbidity
Figure 11: 7MM, diagnosed incident cases of PsA (N), men and women, ages >=18 years, 2023
Figure 12: 7MM, diagnosed incident cases of PsA by sex (N), ages >=18 years, 2023
Figure 13: 7MM, diagnosed incident cases of PsA by age (N), men and women, 2023
Figure 14: 7MM, diagnosed prevalent cases of PsA (N), men and women, ages >=18 years, 2023
Figure 15: 7MM, diagnosed prevalent cases of PsA by sex (N), ages >=18 years, 2023
Figure 16: 7MM, diagnosed prevalent cases of PsA by age (N), men and women, 2023
Figure 17: 7MM, diagnosed prevalent cases by type (N), men and women, ages >=18 years, 2023
Figure 18: 7MM, diagnosed prevalent cases by severity (N), men and women, ages >=18 years, 2023
Figure 19: 7MM, diagnosed prevalent cases of PsA with PsO (N), men and women, ages >=18 years
Figure 20: Unmet needs and opportunities in PsA
Figure 21: Overview of the development pipeline in PsA
Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PsA in the 7MM during the forecast period
Figure 23: Competitive assessment of the marketed and pipeline biologic drugs benchmarked against the SOC, Stelara
Figure 24: Competitive assessment of the marketed and pipeline small molecules drugs benchmarked against the SOC, Rinvoq
Figure 25: Analysis of the company portfolio gap in PsA during the forecast period
Figure 26: Global (7MM) sales forecast by country for PsA in 2023 and 2033
Figure 27: Sales forecast by class for PsA in the US in 2023 and 2033
Figure 28: Sales forecast by class for PsA in the 5EU in 2023 and 2033
Figure 29: Sales forecast by class for PsA in Japan in 2023 and 2033

Psoriatic Arthritis - Seven-Market Drug Forecast and Market Analysis

Description

Table of Contents

List of Tables

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Psoriatic Arthritis: Executive Summary

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Current Treatment Options

7 Unmet Needs and Opportunity Assessment

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Current and Future Players

12 Market Outlook

13 Appendix

List of Table

List of Tables

List of Figure

List of Figures